Sun Pharmaceutical Industries has agreed to acquire Organon in a transaction valued at $11.75 billion, creating what the company described as the largest Biopharma Deal recorded in 2026. The agreement brings together two businesses that each generated $6.2 billion in revenue in 2025, effectively doubling Sun Pharma’s scale and strengthening its global position. Already India’s leading biopharma company, Sun Pharma will significantly expand its presence in women’s health and specialty medicines through the addition of Organon’s portfolio. The transaction is expected to close by early 2027, subject to regulatory approvals and customary conditions.
Under the terms of the agreement, Sun Pharma will pay $14 per share for Organon. The acquisition is expected to enhance Sun’s capabilities in branded pharmaceuticals and biosimilars, pushing the company to No. 7 among global biosimilar players. This strategic move comes as Sun seeks to offset recent pressure in its U.S. generics business by increasing its exposure to higher-value segments. Organon, despite consistent annual revenues between $6.2 billion and $6.4 billion since its spin-off from Merck in 2021, has faced operational challenges. These include debt burdens, upcoming loss of exclusivity for its contraceptive implant Nexplanon, and integration pressures following its $1.2 billion acquisition of Dermavant in 2024. The Dermavant deal added Vtama, a non-steroid dermatology treatment that recorded $128 million in sales in 2025, below the company’s initial target.
Industry analysts note that Organon still offers strategic value through its established product base and experienced workforce. The company traces its origins to 1923 in The Netherlands and now markets more than 70 medicines across approximately 140 countries, supported by manufacturing operations at six sites in Europe. According to analyst Umer Raffat of Evercore ISI, Organon brings “excellent people from Merck” and an “excellent set of legacy Merck brands.” The deal surpasses other major transactions announced this year, including Eli Lilly’s acquisitions of Centessa Pharmaceuticals and Kelonia Therapeutics, valued at $7.8 billion and $7 billion, respectively. Additional activity includes Merck acquiring Terns Pharmaceuticals for $6.7 billion, Biogen purchasing Apellis for $5.6 billion, and Gilead acquiring Tubulis for $5 billion, underscoring a surge in large-scale consolidation across the sector.
Sun Pharma, historically known for its generics portfolio, has been steadily building its specialty business in dermatology, ophthalmology, and oncology-dermatology through targeted acquisitions. These include Concert Pharmaceuticals in 2023 for $576 million and Checkpoint Therapeutics in 2025 for $418 million. Commenting on the latest transaction, managing director Kirti Ganorkar said, “This transaction is a logical next step in strengthening Sun Pharma’s global business,” adding, “Together, we will become a partner of choice for acquiring and launching new products. Our immediate priorities will be business continuity, disciplined integration and responsible value creation. We see strong potential in leveraging Organon’s talent pool.” The Organon acquisition further positions Sun Pharma as a major force in global healthcare, anchored by the year’s most significant Biopharma Deal.
